Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mylène Tajan

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cell Metabolism|November 10, 2016
The Quid Pro Quo of the Tumor/Stromal InteractionMylène Tajan, Karen H Vousden
Cancer Cell|May 16, 2020
Dietary Approaches to Cancer TherapyMylène Tajan, Karen H Vousden
Endocrine Reviews|June 21, 2018
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK PathwayMylène Tajan, Romain Paccoud, Sophie Branka, et al.
European Journal of Medical Genetics|September 6, 2015
SHP2 sails from physiology to pathologyMylène Tajan, Audrey de Rocca Serra, Philippe Valet, et al.
Nature Communications|October 27, 2021
The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cellsMarc Hennequart, Christiaan F Labuschagne, Mylène Tajan, et al.
Biomedicines|September 23, 2022
The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?Céline Saint-Laurent, Laurène Mazeyrie, Mylène Tajan, et al.
Cell Metabolism|August 21, 2018
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3Mylène Tajan, Andreas K Hock, Julianna Blagih, et al.
Human Molecular Genetics|April 17, 2018
Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growthMylène Tajan, Julie Pernin-Grandjean, Nicolas Beton, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureAudrey De Rocca Serra-Nédélec, Thomas Edouard, Karine Tréguer, et al.
The Journal of Clinical Investigation|March 22, 2022
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphomaAnnalisa D'Avola, Nathalie Legrave, Mylène Tajan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cell Metabolism|November 10, 2016
The Quid Pro Quo of the Tumor/Stromal InteractionMylène Tajan, Karen H Vousden
Cancer Cell|May 16, 2020
Dietary Approaches to Cancer TherapyMylène Tajan, Karen H Vousden
Endocrine Reviews|June 21, 2018
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK PathwayMylène Tajan, Romain Paccoud, Sophie Branka, et al.
European Journal of Medical Genetics|September 6, 2015
SHP2 sails from physiology to pathologyMylène Tajan, Audrey de Rocca Serra, Philippe Valet, et al.
Nature Communications|October 27, 2021
The impact of physiological metabolite levels on serine uptake, synthesis and utilization in cancer cellsMarc Hennequart, Christiaan F Labuschagne, Mylène Tajan, et al.
Biomedicines|September 23, 2022
The Tyrosine Phosphatase SHP2: A New Target for Insulin Resistance?Céline Saint-Laurent, Laurène Mazeyrie, Mylène Tajan, et al.
Cell Metabolism|August 21, 2018
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3Mylène Tajan, Andreas K Hock, Julianna Blagih, et al.
Human Molecular Genetics|April 17, 2018
Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growthMylène Tajan, Julie Pernin-Grandjean, Nicolas Beton, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureAudrey De Rocca Serra-Nédélec, Thomas Edouard, Karine Tréguer, et al.
The Journal of Clinical Investigation|March 22, 2022
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphomaAnnalisa D'Avola, Nathalie Legrave, Mylène Tajan, et al.
Pageof 2